Insights
Insights From Our Experts
Articles
Single-Cell Multiomics: Opportunities, Challenges, and the Evolving Business Model
Content for this article was contributed by EVERSANA’s Asia Pacific team. Single Cell Multiomics is a Fast-Growing Market Space with a Wide Range of Applications Single cell multiomics is a new and exciting space in the…
Three Keys to Value for Unlocking the Promise of Cell Therapies
The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1 The revenue generation is being driven…
Challenges of Scaling Up Cell Therapy to New Geographies
Cell therapy has emerged as one of the most promising disruptive innovations in the pharmaceutical industry. However, despite its commercial promise, companies developing cell therapies have not been able to take full advantage of its massive…
Case Study: Defining the Rare Disease Patient Journey to Support Commercialization of Therapy
Rare diseases are complex, and with limited research available, therapeutic options are often limited. Gene therapy, a growing area of clinical research, is showing great promise in treatment that may be life-altering for patients with many…
How Do We Pay for a Cure? How to Put a Price on Life-changing Treatments
The global cell and gene therapy market is expected to reach $13.8 billion by 2026, expanding at a compound annual growth rate of 12.4%. — Global Cell & Gene Therapy Manufacturing Services Market by Type –…
Podcast: Achieving Cell and Gene Therapy Commercial Excellence
There is no question about the incredible clinical impact cell and gene therapies (CGTs) can have on the lives of patients. However, this impact is the result of innovation that does not equate to a simple,…
Gene Therapy in Today’s Digital World
Rare diseases are an emerging global public health priority, with a staggering impact on the more than 300 million people worldwide who are living with them. There are more than 6,000 rare diseases, 72% of which…
THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization
While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical…
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical…
WEBINAR: Reimagining the Patient Journey for CGTs: Informing, Engaging and Empowering the Patient Population
Cell and gene therapies (CGTs) hold great life-saving and therapeutic advancement potential, but their complexity requires careful approach–starting with engaging and educating patient communities earlier. While the patient’s voice should be a guiding force throughout the…